An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B
NCT02554773
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Hemophilia A
Hemophilia B
Interventions
DRUG:
Fitusiran (SAR439774)
Sponsor
Genzyme, a Sanofi Company